Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Patent
1997-01-30
1999-01-12
Kulkosky, Peter F.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
424473, A61K 4732, A61K 922
Patent
active
058583882
ABSTRACT:
A non-abusable, non-inflammatory, biocompatible, non-biodegradable, subcutaneous, polymeric implant for the prolonged, controlled release of hydromorphone with near zero-order kinetics is described. Methods of alleviating cancer pain and treating opioid drug addiction with the implant are also described.
REFERENCES:
patent: 4863736 (1989-09-01), Azain et al.
Rhine, W.D., et al, Journal of Pharmaceutical Sciences, vol. 69, No. 3, pp. 265-270, Mar. 1980, "Polymers for Sustained Macromolecule Release: Procedures to Fabricate Reproducible Delivery Systems and Control Release Kinetics".
Sefton, M.V. et al., Journal of Pharmaceutical Sciences, vol. 73, No. 12, pp. 1859-1861, Dec. 1984, "Ethylene-Vinyl Acetate Copolymer Microspheres for Controlled Release of Macromolecules".
Cohen, J., et al, Journal of Pharmaceutical Sciences, vol. 73, No. 8, pp. 1034-1037, Aug. 1984, "Sintering Technique for the Preparation of Polymer Matrices for the Controlled Release of Macromolecules".
Kuu, Wei-Youh, et al, Journal of Pharmaceutical Sciences, vol. 74, No. 9, pp. 926-933, Sep. 1985, "Multiple-Hole Approach to Zero-Release".
Miyazaki, S., et al, Chem. Pharm. Bull., 29(9)2714-1717 (1981) "Controlled Release of Prednisolone from Ethylene-Vinyl Acetate Copolymer Matrix".
Wyszynski, R.E., et al, Journal of Ocular Pharmacology, vol. 5, N. 2, pp. 141-146 (1989), "Sustained Release of 5-Fluorouracil from Ethylene Acetate Copolymer".
Lin, S.Y., et al, Biomat., Art. Cells, Art. Org., 17(2), 189-203 (1989), "Tumoricidal Effect of Controlled-Release Polymeric Needle Devices Containing Adriamycin HCI in Tumor-Bearing Mice".
Brown, L., et al, Diabetes, vol. 35, pp. 692-697, Jun. 1986, "Controlled Release of Insulin From Polymer Matrices".
Hoffman, D., et al, Experimental Neurology, 110, 39-44 (1990), "NGF Released from a Polymer Matrix Prevents Loss of ChAT Expression in Basal Forebrain Neurons following a Fimbria-Fornix Lesion".
Radomsky, M.L., Biomaterials, vol. 11, 619-24 (1990) "Macromolecules Released From Polymers:Diffusion into Unstirred Fluids".
Niemi, S.M., et al, Laboratory Animal Science, vol. 35, No. 6, 609-612, Dec. 1985, "Evaluation of Ethylene-Vinyl Acetate Copolymers as a Non-Inflammatory Alternative to Freud's Complete Adjuvant in Rabbits".
During, M.J., et al, Annals of Neurology, vol. 25, No. 4, pp. 351-356, Apr. 1989, "Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization".
Sabel, B.A., et al, Annals of Neurology, vol. 28, No. 5, pp. 714-717, Nov. 1990, "Extended Levodopa Release from a Subcutaneously Implanted Polymer Matrix in Rats".
Brown, L.R., et al, Journal of Pharmaceutical Sciences, vol. 72, No. 10, pp. 1181-1185, Oct. 1983, "In Vivo and in Vitro Release of Macromolecules from Polymeric Drug Delivery Systems".
Langer, R., et al, Journal of Biomedical Materials Research, vol. 15, 267-277 (1981) "Biocompatibility of Polymeric Delivery Systems for Macromolecules".
Brook, I.M., et al., British Dental Journal, 157:11 Jul. 7, 1984, "Controlled Delivery of Drug".
Grossman, S.A. et al, Proceddings of ASCO, vol. 10, p. 337, Mar. 1991, "A Non-Abuable Parenteral Narcotic Delivery System for Continous Subcutaneous (SQ) Administration."
Hsieh, D.S.T., et al, Journal of Pharmaceutical Sciences, vol. 72, No. 2, pp. 17-22, Jan. 1983, Zero-Order Controlled-Release Polymer Matrices for Micro-and Macromolecules.
Vallner, J.J., et al, J. Clin. Pharmacol., 21:152-156, 1981; "Pharmacokinetics and Bioavailability of Hydromorphone Following Intravenous and Oral Administration to Human Subjects".
Bruera, E., et al, Journal of the National Cancer Institute, 80:1152-1154 (1988), "Patient-Controlled Subcutaneous Hydromorphone Versus Continuous Subcutaneous Infusion for the Treatment of Cancer Pain".
Reidenberg, M.M., et al, Clin. Pharmacol. Ther., 44:376-82 (1988), "Hydromorphone Levels and Pain Control in Patients with Severe Chronic Pain".
Moulin, D.E., et al, Can. Med. Assoc. J., 146(6) 891-898, Mar. 15, 1992, "subcutaneou Narcotic Infusions for Cancer pain: Treatment Outcome and Guidelines for Use".
Moulin, D.E., et al, Lancet, 337:465-68, Feb. 23, 1991, "Comparison of Continuous Subcutaneous and Intravenous Hydromorphone Infusions for Management of Cancer Pain".
Strain, E.C., et al, Annals of Internal Medicine, vol. 119, No. 1, pp. 23-27, Jul. 1, 1993, "Dose Response Effects of methandone in the Treatment of Opioid Dependence".
Gerstein, D.R., The New England Journal of Medicine, pp. 344-848, Sep. 20, 1990, "Treating Drug Problems".
Grossman Stuart A.
Leong Kam W.
Lesser Glenn J.
Lo Hungnan
Axxia Technologies
Kulkosky Peter F.
LandOfFree
Subcutaneous implant for delivery of hydromorphone does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Subcutaneous implant for delivery of hydromorphone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Subcutaneous implant for delivery of hydromorphone will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1512267